Outcomes of infants born to women infected with hepatitis B

Pediatrics

Volumn 135, Issue 5, 2015, Pages e1141-e1147

  Schillie, Sarah ^a   Walker, Tanja ^b   Veselsky, Steven ^a   Crowley, Susan ^c   Dusek, Cristina ^d   Lazaroff, Julie ^e   Morris, Sandra A ^f   Onye, Kenneth ^g   Ko, Stephen ^a   Fenlon, Nancy ^a   Nelson, Noele P ^a   Murphy, Trudy V ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c MINNESOTA DEPARTMENT OF HEALTH   (United States)

^d FLORIDA DEPARTMENT OF HEALTH   (United States)

^e NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^f TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

^g MICHIGAN DEPARTMENT OF COMMUNITY HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; ASIAN; BIRTH WEIGHT; DISEASE ASSOCIATION; FEMALE; GESTATIONAL AGE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOPROPHYLAXIS; INFANT; INFECTION RISK; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNAL DISEASE; NEWBORN; OUTCOME ASSESSMENT; PACIFIC ISLANDER; PERINATAL INFECTION; PRIORITY JOURNAL; RACE DIFFERENCE; VIRUS LOAD; VIRUS TRANSMISSION; BLOOD; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PROSPECTIVE STUDY; TRANSMISSION; VERTICAL TRANSMISSION;

ADOLESCENT; ADULT; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; PROSPECTIVE STUDIES;

EID: 84929492457     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-3213     Document Type: Article

References (30)

1. Centers for Disease Control and Prevention. Viral hepatitis surveillance- United States, 2010. Available at: www. cdc.gov/hepatitis/Statistics/2010Surveillance/Commentary.htm. Accessed June 26, 2013
2. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. In: Atkinson W, Hamborsky J, Stanton A, Wolfe C, eds. The Pink Book: Course Textbook. 12th ed. Washington, DC: Public Health Foundation; 2012
3. Centers for Disease Control and Prevention. Postvaccination serologic testing results for infants aged 24 months exposed to hepatitis B virus at birth: United States, 2008-2011. MMWR Morb Mortal Wkly Rep. 2012;61:768-771
4. Cheung KW, Seto MT, Wong SF. Towards complete eradication of hepatitis B infection from perinatal transmission: review of the mechanisms of in utero infection and the use of antiviral treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2013;169(1): 17-23
5. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci. 1993; 253(1337):197-201
6. Smith EA, Jacques-Carroll L, Walker TY, Sirotkin B, Murphy TV. The national Perinatal Hepatitis B Prevention Program, 1994-2008. Pediatrics. 2012;129(4):609-616
7. Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet. 1983;2(8359):1099-1102
8. Mast EE, Margolis HS, Fiore AE, et al; Advisory Committee on Immunization Practices. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005;54(RR-16): 1-31
9. André FE, Zuckerman AJ. Review: protective efficacy of hepatitis B vaccines in neonates. J Med Virol. 1994; 44(2):144-151
10. Ronsin C, Pillet A, Bali C, Denoyel GA. Evaluation of the COBAS AmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay. J Clin Microbiol. 2006;44(4): 1390-1399
11. Tseng TC, Liu CJ, Chen CL, et al. Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigennegative carriers by combining viral biomarkers. J Infect Dis. 2013;208(4): 584-593
12. Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol. 2011;26(4): 628-638
13. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol. 1977;105(2): 94-98
14. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ. 2006; 332(7537):328-336
15. McMahon BJ, Schoenberg S, Bulkow L, et al. Seroprevalence of hepatitis B viral markers in 52,000 Alaska Natives. Am J Epidemiol. 1993;138(7):544-549
16. Kohn MA, Farley TA, Scott C. The need for more aggressive follow-up of children born to hepatitis B surface antigenpositive mothers: lessons from the Louisiana Perinatal Hepatitis B Immunization Program. Pediatr Infect Dis J. 1996;15(6):535-540
17. Friedman SM, DeSilva LP, Fox HE, Bernard G. Hepatitis B screening in a New York City obstetrics service. Am J Public Health. 1988;78(3):308-310
18. Cruz AC, Frentzen BH, Behnke M. Hepatitis B: A case for prenatal screening of all patients. Am J Obstet Gynecol. 1987;156(5):1180-1183
19. Ott JJ, Stevens GA, Wiersma ST. The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions. BMC Infect Dis. 2012; 12:131
20. Marion SA, Tomm Pastore M, Pi DW, Mathias RG. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol. 1994;140(8): 734-746
21. Ghendon Y. Perinatal transmission of hepatitis B virus in high-incidence countries. J Virol Methods. 1987;17(1-2): 69-79
22. Xu DZ, Yan YP, Zou S, et al. Role of placental tissues in the intrauterine transmission of hepatitis B virus. Am J Obstet Gynecol. 2001;185(4):981-987
23. Pan CQ, Lee HM. Antiviral therapy for chronic hepatitis B in pregnancy. Semin Liver Dis. 2013;33(2):138-146
24. Deng M, Zhou X, Gao S, et al. The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: A systematic review and meta-analysis. Virol J. 2012;9:185
25. Greenup AJ, Tan PK, Nguyen V, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol. 2014;61(3):502-507
26. Fan L, Owusu-Edusei K Jr, Schillie SF, Murphy TV. Antiviral treatment among pregnant women with chronic hepatitis B. Infect Dis Obstet Gynecol. 2014;2014: 546165
27. Fan L, Owusu-Edusei K Jr, Schillie SF, Murphy TV. Cost-effectiveness of testing hepatitis B-positive pregnant women for hepatitis B e antigen or viral load. Obstet Gynecol. 2014;123(5):929-937
28. Beasley RP, Hwang LY, Lin CC, et al. Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised double-blind placebocontrolled trial. Lancet. 1981;2(8243): 388-393
29. Centers for Disease Control and Prevention. Postexposure prophylaxis of hepatitis B. MMWR Morb Mortal Wkly Rep. 1984;33(21):285-290
30. Beasley RPSC. Vertical transmission of HBV and interruption with globulin. In: Vyas GNCS, Schmid R, eds. Viral Hepatitis. Philadelphia, PA: The Franklin Institute Press; 1978:333-345